Bavarian Nordic has found its new CEO
Six months after Paul Chaplin said he was stepping down as CEO of Bavarian Nordic, the Danish biopharma has named Tarja Stenvall to the role.
Bayer's Kerendia gets broader use in diabetic kidney disease
Bayer's fast-growing Kerendia has had its label extended in the US to include chronic kidney disease associated with type 1 diabetes.
Boehringer launches hub for patient experience data
Boehringer Ingelheim has launched a hub to help patient organisations gather and use patient experience data (PED) more effectively.
NICE finally backs Enhertu for HER2-low breast cancer
Almost three years after Enhertu was made available in Scotland, the drug is finally an option for patients in England with HER2-low breast cancer.
Novo taps Anthropic's Claude AI for drug discovery
Novo adds Anthropic AI models and Claude Science to its drug discovery toolkit in a bid to become "the world's most AI-driven healthcare company."
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
RNA-Targeted Small Molecules: From Discovery to Clinic
Leading pharma, biotech and academic experts discuss the future of RNA therapeutics.
Novel CNS Biomarkers Summit Europe
Europe is rapidly becoming a hub for next-generation CNS biomarker innovation
Who's Speaking at the DIA-MHRA Global Summit 2026?
See who's speaking when regulators and industry convene at the DIA-MHRA Global Summit
4th Cell Therapy for Autoimmune Disease Summit
Developers are racing to overcome challenges around safety, scalability, durability of response, and patient access
10th Complement-Based Drug Development Summit
Uniting leaders pioneering complement-targeted therapies across ophthalmology, neurodegeneration, nephrology, oncology and autoimmune indications